Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063619 · ClinicalTrials.gov registry record · Phase 2
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
A Phase 2 study of Mammographically Dense Breast, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
- 5
- Study locations
NCT03063619 is a Phase 2 study of Mammographically Dense Breast that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 194 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT03063619, a Phase 2 study of Mammographically Dense Breast, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
- 5
- Study locations
Study Summary
This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Afimoxifene
Study Locations (5)
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Columbia University/Herbert Irving Cancer Center - New York
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063619
The ClinicalTrials.gov registry entry for NCT03063619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mammographically Dense Breast appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03063619 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03063619 about?
NCT03063619 is a clinical study titled "Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast". This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the ...
What is the current status of trial NCT03063619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2018-01-30. Estimated completion is 2021-10-26.
What conditions does trial NCT03063619 study?
This clinical trial studies the following conditions: Mammographically Dense Breast.
What interventions are being tested in trial NCT03063619?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Afimoxifene (DRUG).
Who is sponsoring clinical trial NCT03063619?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03063619 being conducted?
This trial has 5 study locations across Florida, Illinois, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.